

# Apton Corporation

[View the current Apton Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/18569-Apton+Corporation.html)

(<http://www.bioportfolio.com/biocorporate/18569-Apton+Corporation.html>)

## Contact Details:

**PO Box 59419**

**Philadelphia**

**Pennsylvania**

**19102-9419**

**United States of America**

Tel: 215-218-4340

Fax: 215-218-4357

Email: [ir@aphton.com](mailto:ir@aphton.com)

Apton Corporation, headquartered in Philadelphia, Pennsylvania, is a clinical stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. Apton's products seek to empower the body's own immune system to fight disease. Through the acquisition of Igeneon AG in March 2005, Apton acquired late-stage products, IGN101, a cancer vaccine designed to induce an immune response against EpCAM-positive tumor cells, and IGN311, a fully humanized antibody against the Lewis Y antigen. Apton has strategic alliances with Xoma for treating gastrointestinal and other gastrin-sensitive cancers using anti-gastrin monoclonal and other antibodies; Daiichi Pure Chemicals for the development, manufacturing and commercialization of gastrin-related diagnostic kits; and Celltrion, Inc. for the development, manufacturing and commercialization of IGN311. Apton's most advanced product, Insegia™, targets the hormone gastrin 17 in an attempt to treat gastrointestinal cancers. Apton is currently seeking partners that will support the further development of Insegia.

## Recent Publications by Apton Corporation:



- [Vaccines and monoclonal antibodies.](#)

*The immunoglobulin molecule contains structural features that make it a...* 4th March, 2006  
Apton Corporation,- Semin Oncol. 2005 Dec;32(6 Suppl 9):S82-6. ([DOI Direct Link](#))

## Press Releases on Apton Corporation:

<a href="#">Centene Corporation to Present at Bank of America Merrill Lynch Credit Conference</a>	20th November, 2009	Centene Corporation	ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) today announced that it will present at the Bank of America Merrill Lynch 2009 Credit Conference, to be held December 2-3,
<a href="#">Reportlinker Adds Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015</a>	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide,
<a href="#">Reportlinker Adds Medical Adhesives and Sealants - A US Market Review</a>	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Medical Adhesives and Sealants - A US Market Review <a href="http://www">http://www</a>
<a href="#">Reportlinker Adds Toothpaste - Global Market Trends</a>	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Toothpaste - Global Market Trends <a href="http://www.reportlinker.com/p0164389">http://www.reportlinker.com/p0164389</a>
<a href="#">Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth</a>	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to

**Apton Corporation Clinical Trials:**



- [Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer](#)



## Apton Corporation Patents:

- 6861510- [Immunogenic compositions against gastrin peptides](#)
- 4814170- [Method for immunization against and treatment of infection by ectoparasites and endoparasites](#)
- 4891219- [Method for immunization against and treatment of infection by ectoparasites and endoparasites](#)
- 5023077- [Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease](#)
- 5468494- [Immunogenic compositions against human gastrin 17](#)
- 5607676- [Immunogenic compositions against gastrin peptides](#)
- 5609870- [Methods for the preparation of immunogens against gastrin](#)
- 5622702- [Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease](#)
- 5688506- [Immunogens against gonadotropin releasing hormone](#)
- 5785970- [Method of the treatment of gastrointestinal disorders with immunogenic compositions against gastrin](#)
- 5866128- [Method for the treatment and prevention of gastric and duodenal ulcer](#)
- 6132720- [Immunogens against gonadotropin releasing hormone](#)
- 6303123- [Methods for the treatment of hormone-dependent tumors with immunogens against gonadotropin releasing hormone](#)
- 6359114- [System for method for the modification and purification of proteins](#)
- 6548066- [Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors](#)
- 6783761- [Chimeric peptide immunogens](#)
- 4795634- [Method for contraception by immunization against the zona pellucida](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

